Status:
COMPLETED
Prognostic Evaluation of 18fmiso Pet-ct in Head and Neck Cancer
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Cancer of Head and Neck
Head and Neck Neoplasms
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Head and neck cancer is the sixth most frequent cancer worldwide, excluding lymphomas and skin cancer. If 18FDG PET is considered today as a standard tool in patients with head and neck squamous cell ...
Detailed Description
Hypoxia is one of the major worst prognostic factors of clinical outcome in cancer. It is actually admitted that hypoxia is heterogeneous, variable within different tumour types and that it varies spa...
Eligibility Criteria
Inclusion
- Patients over 18
- Patients presenting a squamous cell head and neck carcinoma proposed for a radical treatment consisting in conformational radiotherapy with or without chemotherapy or associated targeted therapy
- Signed informed consent
Exclusion
- Patients with distant metastases known before inclusion
- Patients suffering of a second cancer or treated before by radiotherapy in the tumour site.
- Pregnancy
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01235052
Start Date
June 1 2009
End Date
July 1 2014
Last Update
August 10 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux - Hôpital Pellegrin
Bordeaux, France, 33 076
2
Hôpital Robert Picqué
Villenave-d'Ornon, France, 33882